Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
- PMID:24084047
- PMCID: PMC3945037
- DOI: 10.1016/j.lfs.2013.09.017
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Abstract
K2 or Spice products are emerging drugs of abuse that contain synthetic cannabinoids (SCBs). Although assumed by many teens and first time drug users to be a "safe" and "legal" alternative to marijuana, many recent reports indicate that SCBs present in K2 produce toxicity not associated with the primary psychoactive component of marijuana, ∆(9)-tetrahydrocannabinol (Δ(9)-THC). This mini-review will summarize recent evidence that use of K2 products poses greater health risks relative to marijuana, and suggest that distinct pharmacological properties and metabolism of SCBs relative to Δ(9)-THC may contribute to the observed toxicity. Studies reviewed will indicate that in contrast to partial agonist properties of Δ(9)-THC typically observed in vitro, SCBs in K2 products act as full cannabinoid receptor type 1 (CB1R) and type 2 (CB2R) agonists in both cellular assays and animal studies. Furthermore, unlike Δ(9)-THC metabolism, several SCB metabolites retain high affinity for, and exhibit a range of intrinsic activities at, CB1 and CB2Rs. Finally, several reports indicate that although quasi-legal SCBs initially evaded detection and legal consequences, these presumed "advantages" have been limited by new legislation and development of product and human testing capabilities. Collectively, evidence reported in this mini-review suggests that K2 products are neither safe nor legal alternatives to marijuana. Instead, enhanced toxicity of K2 products relative to marijuana, perhaps resulting from the combined actions of a complex mixture of different SCBs present and their active metabolites that retain high affinity for CB1 and CB2Rs, highlights the inherent danger that may accompany use of these substances.
Keywords: CB1 receptors; CB2 receptors; Drug abuse; Drug metabolism; K2/Spice; Synthetic cannabis; ∆(9)-Tetrahydrocannabinol.
© 2013.
Conflict of interest statement
The authors declare that they have no financial or personal conflicts of interest that influenced, or could be perceived to have influenced, this work.
Figures




Similar articles
- Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.Tai S, Fantegrossi WE.Tai S, et al.Curr Top Behav Neurosci. 2017;32:249-262. doi: 10.1007/7854_2016_60.Curr Top Behav Neurosci. 2017.PMID:28012093Free PMC article.Review.
- Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA.Castaneto MS, et al.Drug Alcohol Depend. 2014 Nov 1;144:12-41. doi: 10.1016/j.drugalcdep.2014.08.005. Epub 2014 Aug 18.Drug Alcohol Depend. 2014.PMID:25220897Free PMC article.Review.
- Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL.Rajasekaran M, et al.Toxicol Appl Pharmacol. 2013 Jun 1;269(2):100-8. doi: 10.1016/j.taap.2013.03.012. Epub 2013 Mar 26.Toxicol Appl Pharmacol. 2013.PMID:23537664Free PMC article.
- Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD.Sholler DJ, et al.Pharmacol Biochem Behav. 2020 Dec;199:173059. doi: 10.1016/j.pbb.2020.173059. Epub 2020 Oct 18.Pharmacol Biochem Behav. 2020.PMID:33086126Free PMC article.Review.
- Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL.Brents LK, et al.PLoS One. 2011;6(7):e21917. doi: 10.1371/journal.pone.0021917. Epub 2011 Jul 6.PLoS One. 2011.PMID:21755008Free PMC article.
Cited by
- In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.Marusich JA, Gamage TF, Zhang Y, Akinfiresoye LR, Wiley JL.Marusich JA, et al.Pharmacol Biochem Behav. 2022 Oct;220:173467. doi: 10.1016/j.pbb.2022.173467. Epub 2022 Sep 22.Pharmacol Biochem Behav. 2022.PMID:36154844Free PMC article.
- Legal highs: staying on top of the flood of novel psychoactive substances.Baumeister D, Tojo LM, Tracy DK.Baumeister D, et al.Ther Adv Psychopharmacol. 2015 Apr;5(2):97-132. doi: 10.1177/2045125314559539.Ther Adv Psychopharmacol. 2015.PMID:26240749Free PMC article.Review.
- Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.Ford BM, Franks LN, Radominska-Pandya A, Prather PL.Ford BM, et al.PLoS One. 2016 Dec 9;11(12):e0167240. doi: 10.1371/journal.pone.0167240. eCollection 2016.PLoS One. 2016.PMID:27936172Free PMC article.
- Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.Weinstein AM, Rosca P, Fattore L, London ED.Weinstein AM, et al.Front Psychiatry. 2017 Aug 23;8:156. doi: 10.3389/fpsyt.2017.00156. eCollection 2017.Front Psychiatry. 2017.PMID:28878698Free PMC article.Review.
- The Changing Face of Recreational Drug Use.Baumann MH.Baumann MH.Cerebrum. 2016 Jan 1;2016:cer-01-16. eCollection 2016 Jan-Feb.Cerebrum. 2016.PMID:27408674Free PMC article.
References
- Aceto MD, Scates SM, Martin BB. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol. 2001;416:75–81. - PubMed
- Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91:1585–614. - PubMed
- Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;119:123–9. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources